A review on herbal Nrf2 activators with preclinical evidence in cardiovascular diseases

Abu Mohammad Syed1, Chetan Ram1, Upadhyayula Suryanarayana Murty1

  • 1Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Guwahati, Assam, India.

Insights

The nuclear factor E2-related factor 2 (Nrf2) pathway shows promise in protecting the heart from cardiovascular diseases (CVDs). Activating Nrf2, especially with herbal compounds, may offer new therapeutic strategies for CVDs.

Area of Science:

  • Cardiovascular research
  • Molecular biology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of death, often linked to oxidative stress and reactive oxygen species (ROS).
  • Oxidative cellular damage contributes to pathological conditions like endothelial dysfunction, cardiac hypertrophy, and heart failure.
  • The Nrf2-Keap1 pathway is a critical regulator of cellular defense against oxidative stress.

Purpose of the Study:

  • To review the molecular mechanisms of Nrf2 in cardiovascular health.
  • To explore the therapeutic potential of Nrf2 activators, particularly herbal compounds, for CVDs.
  • To highlight Nrf2 activation as a potential therapeutic strategy for CVD prevention and treatment.

Main Methods:

  • Literature review of experimental models of cardiac diseases.
  • Analysis of molecular mechanisms underlying Nrf2's role in cardiovascular protection.
  • Examination of findings on herbal Nrf2 activators in preclinical studies.

Main Results:

  • Evidence supports the cardioprotective effects of Nrf2 in various experimental CVD models.
  • Nrf2 activation mitigates oxidative stress and related cellular damage in the heart.
  • Herbal compounds show potential in activating the Nrf2 pathway for therapeutic benefit.

Conclusions:

  • The Nrf2 pathway is a significant target for combating oxidative stress in CVDs.
  • Herbal-derived Nrf2 activators represent a promising therapeutic avenue for cardiovascular conditions.
  • Further clinical validation of Nrf2 activation is needed for CVD treatment.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...